Sofinnova Partners closes €725M Crossover II Fund

  • Backing late-stage life sciences companies through to clinical development, global expansion and commercialization.
  • Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets.

 

PARIS, France – November 16, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD).

Read more…

© Optimum Strategic Communications.